Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1484650

Cost-Effectiveness Analysis of Anlotinib Plus Chemotherapy with or without Benmelstobart Versus Chemotherapy Alone for Extensive-Stage Small-Cell Lung Cancer in China

Provisionally accepted
Caicong You Caicong You 1,2Bin Zheng Bin Zheng 1,2Jiahao Zhang Jiahao Zhang 1,2Jianying Lei Jianying Lei 1,2Wu Fu Wu Fu 1,2Maobai Liu Maobai Liu 1,2*Na Li Na Li 1,2*
  • 1 Fujian Medical University Union Hospital, Fuzhou, China
  • 2 School of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

    The ETER701 trial demonstrated that benmelstobart combined with anlotinib and etoposide-carboplatin (EC) significantly extends survival in patients with extensive-stage small cell lung cancer (ES-SCLC), setting a new record for median overall survival. In contrast, anlotinib plus EC only significantly prolongs progression-free survival. However, there is currently no evidence evaluating the cost-effectiveness of these regimens as first-line treatments. Therefore, this study assesses the cost-effectiveness of these three first-line treatment options from the perspective of the Chinese healthcare system.A time-varying Markov model was constructed to simulate the disease progression of a 62-year-old patient with ES-SCLC, assessing direct medical costs, health benefits, and incremental cost-effectiveness ratios (ICER). Both flexible and standard parametric models were included to fit and extrapolate survival data. The probabilities, costs, and health utilities required for the model were sourced from literature, databases, and expert consultations. Additionally, sensitivity and scenario analyses were conducted to explore the impact of various parameters on model uncertainty.

    Keywords: Cost-effectiveness1, Benmelstobart2, Anlotinib3, Extensive-stage small-sell lung4, Scenario Analysis5, R software6, Time-varying Markov7

    Received: 22 Aug 2024; Accepted: 29 Nov 2024.

    Copyright: © 2024 You, Zheng, Zhang, Lei, Fu, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Maobai Liu, Fujian Medical University Union Hospital, Fuzhou, China
    Na Li, Fujian Medical University Union Hospital, Fuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.